Replies to post #212758 on Amarin Corp Plc (AMRN)

[Atom0aks]

Atom,

"4.8% of people who experience a primary efficacy end point"

That statement cannot be correct...think about it.

My other post got deleted, but I wanted to make sure you knew you were right.

That should have read, "4.8% of people on Vascepa who did not experience a primary efficacy end point" (i.e. deaths prevented by treatment)

Sorry for the confusion!